The platform functions as a centralized web portal, consolidating drug research into six distinct modules ranging from core reagents and target validation to pharmacology and IND-enabling studies. Currently, the hub hosts nearly 70 modularized technology platforms, allowing researchers to tackle development programs across nine primary disease areas, including oncology, neurology, and autoimmune conditions.

Dr. Lang Guojun, CEO of Sanyou Bio, noted that the platform is built to address the inherent complexities of modern pharmaceutical development. By utilizing AI-STAL and the Sanyou AI-Drug Accelerator, the system supports a wide array of modalities, such as bispecific antibodies, antibody-drug conjugates, and CAR-T cell therapies.

Clicklinks facilitates collaboration through flexible partnership models, including joint investments, co-development agreements, and product alliances. With an existing network of over 2,000 pharmaceutical and biotech partners, the company is positioning this hub to serve as a primary engine for resource sharing and collective problem-solving in the life sciences sector.